Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial.
Data from APHINITY study shows Roche’s Perjeta-based regimen reduces the risk of disease returning for people with HER2-positive early breast cancer - News - PharmaTimes
Greatest benefit continued to be seen in people who are at a high risk of recurrence (those with lymph node-positive disease)With longer follow-up, treatment effect continues to be seen regardless of hormone